Drug Profile
Adalimumab biosimilar - Tanvex Biopharma
Alternative Names: Humira® biosimilar - Tanvex Biopharma; TX17Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Tanvex BioPharma
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Taiwan (SC, Injection)
- 22 Feb 2018 Preclinical trials in Rheumatoid arthritis in Taiwan (unspecified route) (Tanvex pipeline, February 2018)